Advertisement

Topics

Shield Therapeutics Company Profile

02:01 EDT 26th March 2019 | BioPortfolio

Shield, founded in 2008, is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. Shield is currently preparing to undertake a global pivotal Phase III study of its lead asset, ST10-021, for the treatment of iron deficiency anaemia associated with inflammatory bowel disease. The Company is headquartered in Wollerau, Switzerland. For further information, please visit http://www.shieldtherapeutics.com.


News Articles [964 Associated News Articles listed on BioPortfolio]

Shield Therapeutics - Fortified for growth

Edison Investment Research - Pharmaceuticals & healthcare - Shield Therapeutics: Shield Therapeutics is focused on the development and commercialisation of Feraccru, a CHMP-approved oral formulatio...

Shield Therapeutics (STX) - Fortified for growth

Edison Investment Research - Pharmaceuticals & healthcare - Shield Therapeutics: Shield Therapeutics is focused on the development and commercialisation of Feraccru, a CHMP-approved oral formulation o...

Shield Therapeutics (STX) - Feraccru performs again in a Phase III study

Edison Investment Research - Pharmaceuticals & healthcare - Shield Therapeutics: Shield Therapeutics has announced positive top-line data from a Phase IIIb study (AEGIS-H2H) for Feraccru, a CHMP-appro...

Shield Therapeutics Announces the NDA for Feraccru has been Accepted for Filing and Review by FDA

London, UK, 3rd December 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical need...

Shield Therapeutics’ Feraccru yields positive results in extended phase 3 trial

The AEGIS-CKD study of Feraccru was a phase 3 randomized, placebo-controlled, double-blind trial. Compared to placebo, Shield Therapeutics’ ferric iron therapy showed superiority in changing haemogl...

Shield Therapeutics Feraccru yields positive results in extended phase 3 trial

The AEGIS-CKD study of Feraccru was a phase 3 randomized, placebo-controlled, double-blind trial. Compared to placebo, Shield Therapeutics’ ferric iron therapy showed superiority in changing haemogl...

Shield Therapeutics Announces Submission of a New Drug Application (NDA) for Feraccru for the treatment of Iron Deficiency

London, UK, 1st October 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, ...

US FDA to make decision on Shield Therapeutics’ Feraccru drug by end of July

The US is a huge and potentially lucrative market that Shield is understandably keen to crack

PubMed Articles [499 Associated PubMed Articles listed on BioPortfolio]

Thrombogenicity assessment of Pipeline Flex, Pipeline Shield, and FRED flow diverters in an in vitro human blood physiological flow loop model.

Endovascular treatment of intracranial aneurysms with endoluminal flow diverters (single or multiple) has proven to be clinically safe and effective, but is associated with a risk of thromboembolic co...

Calculation model of the equivalent spiral shear stress of conditioned sand.

Soil is the medium that balances the soil and water pressure on the excavation surface of an earth pressure balance (EPB) shield machine, and the soil flow plasticity directly affects the working perf...

Effect of socket-shield technique on alveolar ridge soft and hard tissue in dogs.

To study the soft and hard tissue alterations of the alveolar ridge after socket-shield technique.

Iron delivery from liquid-core hydrogels within a therapeutic nipple shield.

To aid oral therapeutic administration to infants, a novel delivery technology, referred to as a Therapeutic Nipple Shield (TNS), was previously developed. It consists of a silicone nipple shield devi...

Socket-shield technique: the influence of the length of the remaining buccal segment of healthy tooth structure on peri-implant bone and socket preservation. A study in dogs.

The aim of this study was to evaluate the influence of the location and length of root pieces on buccal peri-implant bone width and socket preservation in socket shield technique.

Clinical Trials [208 Associated Clinical Trials listed on BioPortfolio]

Influence of the Brownie Breast Shield on the Dynamics of Milk Removal

The purpose of this study is to investigate the efficacy of breast drainage of the healthy breast with the new Medela pump set breast shield (Brownie). The objective of the study is to ve...

I-ZIP Ocular Bandage Pivotal Study

To evaluate the safety and performance of the I-ZIP Ocular Bandage in subjects undergoing uneventful unilateral clear corneal phacoemulsification with foldable monofocal intraocular lens (...

Comparison of Peri-implant Tissues Using Socket Shield Technique Versus Xenograft

The aim of this study is to clinically and radiographically evaluate the dimensional changes of soft and hard peri-implant tissues around single immediate post-extraction implants in the e...

Impact of Breast Shield Designs on Dynamics of Breast Pumping

A prospective, randomized, 2-phase/crossover, single center premarket feasibility study. In phase I the comfort will be assessed, the occurence and types of adverse events will be recorded...

Socket Shield Technique Versus Conventional Immediate Implant Placement in Thin Buccofacial Bone

Buccal bone is prone to resorb after tooth extraction specially with immediate tooth implantation which could compromise the esthetics of the patient. socket shield technique retains the b...

Companies [1459 Associated Companies listed on BioPortfolio]

Shield Therapeutics

Shield, founded in 2008, is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address a...

Blue Cross and Blue Shield of Georgia, Inc.

Blue Cross and Blue Shield of Georgia, Inc. and Blue Cross and Blue Shield Healthcare Plan of Georgia, Inc. are independent licensees of the Blue Cross and Blue Shield Association(® ). The Blue Cross...

Blue Cross and Blue Shield of Georgia

Blue Cross and Blue Shield of Georgia, Inc. and Blue Cross and Blue Shield Healthcare Plan of Georgia, Inc. are independent licensees of the Blue Cross and Blue Shield Association® . The Blue Cross a...

Blue Cross Blue Shield of Georgia

Blue Cross and Blue Shield of Georgia, Inc. and Blue Cross and Blue Shield Healthcare Plan of Georgia, Inc. are independent licensees of the Blue Cross and Blue Shield Association® . The Blue Cross a...

Blue Cross and Blue Shield of Georgia (BCBSGa)

Blue Cross and Blue Shield of Georgia, Inc. and Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. are independent licensees of the Blue Cross Blue Shield Association. The Bl...

More Information about "Shield Therapeutics" on BioPortfolio

We have published hundreds of Shield Therapeutics news stories on BioPortfolio along with dozens of Shield Therapeutics Clinical Trials and PubMed Articles about Shield Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Shield Therapeutics Companies in our database. You can also find out about relevant Shield Therapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


Corporate Database Quicklinks



Searches Linking to this Company Record